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(DITORIAL COMMENT
acing Away From Bias*
onathan D. Sackner-Bernstein, MD, FACC,
al A. Skopicki, MD, PHD
anhasset, New York
etrospective and subgroup analyses have created a means
o dissect clinically relevant subgroups that may otherwise
e difficult to study. Although often provocative and
ypothesis-generating, these analyses have been used by
any to dictate clinical practice. This is especially true of
ubgroup analyses from large, prospective multicenter stud-
es in regards to race. Such an approach has led to several
erceptions that shape current medical practice. These
nclude: 1) that African Americans are at higher risk of
eveloping cardiovascular disease than whites (1); 2) that
frican-American hypertensives are best treated with di-
retics or calcium blockers instead of angiotensin-
onverting enzyme inhibitors or beta-blockers (2); 3) that
frican Americans have a worse outcome once developing
See page 778
entricular dysfunction (3); 4) that the effect of beta-blocker
herapy for African Americans with heart failure relative to
hites is not consistent across the beta-blocker therapeutic
lass, with bucindolol being associated with a higher risk of
eath (4) and carvedilol associated with having equal efficacy
5); and 5) that African Americans with heart failure might
ot respond as well as whites to long-term angiotensin-
onverting enzyme inhibitor therapy (6,7). The literature is
ess clear about the risk of death in heart failure based upon
ace, with reports both of increased (1,8) and reduced risk
9,10). More consistent reports of increased risk of hospi-
alization are present (11,12).
In this issue of the Journal, Deswal et al. (12) investigated
he risks of death and hospitalization for African Americans
ith heart failure relative to whites, and by using the
eterans Affairs (VA) national database, minimized the
onfounding factor of differential access to care between
aces. Although the database relies on administrative rather
han clinical data sources, it does provide a large population
ource to be queried. Using rigorous statistical methods, the
ata show that African Americans and whites in the VA
ystem are at equal risk of hospital readmission, and because
he total outpatient visits were similar between African
mericans and whites, the authors conclude that providing
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Clinical Scholars Program, Heart Failure and Cardiomyopathy Center,porth Shore University Hospital, Manhasset, New York.qual access to care eliminated racial differences in care. The
uthors also reported a lower risk of death for African
mericans with heart failure at both 30 days and one year
fter the index hospitalization. Both findings are statistically
obust, unaffected by the introduction of appropriate covari-
tes. However, a major limitation of any retrospective
nalyses, particularly those relying on an administrative
atabase, is the inability to ensure that the two groups
tudied were at equal risk (13).
It is possible that the African-American cohort would
ave a higher rate of rehospitalization than a cohort of
hites with identical baseline risk but that the risks instead
ppeared equal because the African Americans in the VA
ystem had less advanced disease, a possibility supported by
he lower mortality rates at 30 days and one year (12). This
ould not be surprising if there were inequalities in disease
everity or access to ancillary services, information and
ounseling (i.e., diet, exercise), but an administrative data-
ase cannot address these possibilities. Hypothetically, con-
ider a group of African Americans who were modestly
icker than this cohort, sufficient enough to increase their
ortality rate higher but still significantly less than the
ortality risk of the cohort of white patients. In this
ypothetical model, the risk of hospitalization should in-
rease as well. The equivalent rate of readmission then
rgues that African Americans are at higher risk than is
uggested by their disease severity, where disease severity is
easured by mortality rate. Because the findings of their
tudy indicate that readmission rates and mortality may be
ffected differentially in the population studied, as has been
reviously reported (11), these disparities warrant further
nvestigation (12). Therefore, a reader should not draw the
onclusion that universal access to care equalizes the risk for
frican Americans and whites. Instead, these data further
trengthen this perspective as a hypothesis.
The authors provide several explanations for the equal
isk of hospitalization with a lower risk of death, but three
thers should be considered. First, by using the emergency
epartment instead of the clinics, African Americans may
e entering an environment where they are more likely to be
dmitted. Second, even though a previous heart failure
ospitalization portends an increased risk of death (14), the
erception that the risk of heart failure hospitalization is
elated to disease severity, particularly as reflected by func-
ional limitation, has not been prospectively tested and may
e wrong. Third, treatment differences could be due in part
o biases that influence decision-making (15). Although
eswal et al. (12) do not directly address this possibility, the
otential for racism in clinical investigation and clinical
ractice is difficult to control.
As has been reviewed elsewhere, the use of race to
ategorize people extends from anthropologists attempting
o understand the geographic distribution of homo sapiens
16). In the mid 1700s, people were categorized by both
hysical and psychological characteristics, and by the end of
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Editorial Comment March 3, 2004:785–6hat century, the terms race and Caucasian were introduced,
he latter to describe the residents of the Caucasus region of
sia (16). (The most prominent group in the region today
s the Chechens.)
In clinical investigation, categorizing people based on
kin color is not an appropriate scientific approach because
kin color is not a biologic characteristic. As Goldstein and
hikhi report (17), the genetic differences between groups
ccount for only 15% of the genetic variation seen across
ur species. As an example, Wilson et al. (18) surveyed
he genetic homology among eight ethnic groups, focus-
ng on the CYP2D6 hepatic enzyme system. Three of the
roups were of African origin; yet, 62% of the Ethiopians
nd 21% of the Afro-Caribbeans were similar to Western
uropean groups of Norwegians and Ashkenazi Jews. In
ontrast 24% of Ethiopians and 73% of the Afro-
aribbeans were like the Bantu. Should Ethiopians be
onsidered Norwegian and Afro-Caribbeans be consid-
red African? Additional studies point out the disparities
hat can exist for women and men because in many
eographic regions there was unidirectional mating, as
ale explorers inhabited new lands (19).
Race is an important surrogate, but it is only a surrogate.
ealth-related differences that exist between races are not
aused by belonging to a particular race, but rather are likely
ue to associated differences in social, educational, religious,
r economic factors (20), in addition to genetic differences
17,21,22). The clinical perspective must remain focused on
he aggressive treatment of cardiovascular diseases, but
ecause race is not a relevant biologic grouping, our per-
pectives about mechanisms of disease, access to care, and
ffects of therapeutics must shift from a phenomenological
o a genomic paradigm (16,21,22). We need to become
cientifically color blind even while our society is not. The
eswal et al. (12) data facilitate the social arguments for
rospectively testing the role of universal access as a means
o equalize care but should not be used an argument to
rove that this has occurred.
We live in a rich, advanced society. Our medical care is
rguably the best in the world, and providing equal access to
ll can reduce risks. But to have maximum impact, we need
ore than equal access. Identifying what we mean when we
ubgroup according to race is critical; altering treatments or
ccess to care based on blanket characterizations of race in
he absence of a biologic basis cannot be justified. Unless
rospectively controlled studies focusing on specific ethnic
roups prove the usefulness of different clinical approaches,
are must be blind to race and instead focus on treatable
isks, such as hypertension, diabetes, and dyslipidemia.
liminating biases in this context will improve the quality of
ealth care one patient at a time.eprint requests and correspondence: Dr. Jonathan D.
ackner-Bernstein, Division of Cardiology, 1st Floor Cohen,
orth Shore University Hospital, 300 Community Drive,
anhasset, New York 11030. E-mail: jonathansb@yahoo.com.
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